Cerebral Amyloid Angiopathy and Cerebrovascular Dysfunction

Cerebral amyloid angiopathy (CAA) occurs sporadically in elderly populations or in familial forms of Alzheimer’s disease (AD) and is characterized by insoluble deposition of amyloid-beta peptides (Aβ), within arterial vessels of the central nervous system. Amyloid precursor protein is processed by β- and γ-secretases generating Aβ1-40 and Aβ1-42 species that exist as soluble monomers, soluble oligomers (toxic intermediate species), and insoluble fibrils (principle component of CAA) [1]. Of interest, the co-morbidity and relationship between vascular compromise and neurodegenerative processes are not fully understood. CAA is an associated risk factor for intracerebral hemorrhage and ischemic stroke and also may contribute to the cognitive decline observed in aging, AD, or both [1]. Most AD cases feature early decreases in cerebral perfusion that may arise as a consequence of peripheral vascular disease (e.g., type II diabetes, hypertension) and/or loss of basolateral cholinergic innervation that regulates cerebral blood flow (CBF) among other neurological functions [2]. Much remains to be understood concerning CAA-induced vasomotor impairment and its impact toward the occurrence and/or progression of impaired cognitive function within neurodegenerative diseases.

Amyloid Beta, Oxidative Stress, and Vasomotor Function

The effects of Aβ on cerebral blood flow are evident in multiple experimental paradigms. Ex vivo studies that examined the functional effects of monomeric Aβ on isolated cerebral arterioles show that synthetic Aβ1-40 (and to a lesser degree Aβ1-42) causes direct vessel constriction, enhanced response to vasoconstrictors, and reduced response to vasodilators [3,4]. In vivo studies have shown that 6 month-old Tg2576 mice (a common AD model that overexpresses human familial amyloid precursor protein mutation and develops CAA after approximately 12 months of age) have reduced baseline cerebral blood flow and decreased cerebrovascular responses to topiical vasodilators [5-7]. Our lab has shown that cortical arterioles of 6 month-old Tg2576 mice have reduced vascular reactivity to hypercapnia and topical vasodilators, and established for the first time that these cerebrovascular deficits are reduced by depleting soluble Aβ via γ-secretase inhibition [8]. Hence, Aβ species appear to interfere with the vasomotor machinery directly or by induced intermediate factors.

In health tissue endothelium exerts diverse effects within arterial walls of vessels within the brain and on nearby target cells to inhibit vascular tone and vascular growth, protect against thrombosis, and other protective effects [9]. Much of the influence of endothelium on other cells is mediated by intercellular signals carried by diffusible factors, such as nitric oxide (NO) produced by the endothelial form of NO synthase (eNOS). Impairment of eNOS-driven signals underlies vascular dysfunction in a broad spectrum of diseases and is a risk factor for cerebrovascular events and stroke [9]. Reactive oxygen species (ROS) are thought to play a major role in vasomotor dysfunction by efficiently reacting with NO to form the reactive nitrogen anion peroxynitrite, which in turn wreaks havoc by nitrosylating tyrosine and other amino acid residues on protein substrates affecting important cell signaling and structural interactions [9]. ROS mediated impairment is not limited to the eNOS signaling cascade but may also affect other endothelial-derived factors that play a role in vascular regulation (e.g. endothelial derived hyperpolarizing factor) [9].

Interestingly, monomeric Aβ species cause a hyper-contractile vascular phenotype in vascular smooth muscle cells (VSMCs) potentiated by ROS-induced endothelial cell (EC) dysfunction, which suggests a strong link between a presumed cause of neuronal cell dysfunction and vascular/blood flow impairment [10,11]. Aβ fibrils and plaques can potentiate oxidative stress, microglial activation and induce vascular dysfunction in the cerebral circulation that contributes to neuronal cell death [12]. Moreover, it has been suggested that Aβ increases NADPH oxidase activity in the vasculature resulting in increased production of highly reactive oxygen species, superoxide [10] (Figure 1).

Cerebral Amyloid Angiopathy and Oxidative Stress

CAA is seen predominantly in cortical and penetrating cerebral arterioles and is composed predominantly of Aβ1-42 [13]. Vascular dysfunction associated with CAA is not simply due to structural changes but may have deleterious effects on both ECs and VSMCs. The effect of soluble vs. insoluble Aβ load on cerebral blood flow is
highly debated, much evidence exists to suggest that soluble Aβ does affect the functionality of cerebral blood vessels independent of that induced by vascular Aβ deposits [4,8]. Many studies (but not all [11]) suggest that VSMC dysfunction not only contributes to CAA-induced cerebrovascular impairment and is likely a predominant cellular event. CAA-laden vessels from transgenic mice and humans develop substantial vascular functional impairment and VSMC degeneration in advanced stages of the disease [8]. CAA-induced VSMC-mediated vasomotor dysfunction begins prior to significant VSMC loss, indicating that CAA (or soluble Aβ) species in equilibrium with CAA likely induces cerebral arteriole dysfunction through means outside of direct Aβ-induced cytotoxicity [8], which suggests that CAA induces endothelium-independent vessel dysfunction via unidentified molecular effectors likely to be ROS. Other gaps in knowledge include the upstream molecules that mediate the Aβ-induced vascular dysfunction and may include pro-inflammatory mediators [12].

**Potential Therapies**

Anti-amyloid therapies that target both CAA and parenchymal Aβ deposits are of great interest and have lead to numerous strategies and lead compounds. Recent advances in pharmacotherapy include small molecule inhibitors of amyloid precursor protein secretase complexes that inhibit the production of Aβ and humanized monoclonal antibodies recognizing epitopes within primary structure of the Aβ peptide. These strategies have also met unforeseen complications in that within clinical trials of immunotherapies have cleared brain parenchymal Aβ, but also increased vascular Aβ deposition increasing the risk of cerebral hemorrhage [14]. Passive immunization with designer antibodies lacking the Fc-receptor activity and do not activate effector cells has been suggested as an approach to effectively target the Aβ burden and avoid detrimental inflammatory effects associated with other immunotherapies [14]. Anti-ROS therapy via ROS scavenger molecules or inhibition of ROS generating enzymes (e.g., NADPH oxidase) in animal models has been successful in ameliorating cardiovascular disease in animal models, but results from human studies are largely disappointing [9]. The impact of anti-ROS therapy on the formation of CAA and related blood vessel function is of great interest in both future animal and human trials. Additionally, new imaging technologies that specifically identify CAA are in current development with the ultimate goal to aid the assessment of the disease classification within patients [15]. It is with great anticipation and effort that we look for the impact that these potential therapies will have on the structural and functional effects of Aβ and CAA on cerebral vasculature.

**References**